- Home
- ALCYU vs IMNM Comparison
ALCYU vs IMNM Comparison
Compare ALCYU & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALCYU
- IMNM
- Stock Information
- Founded
- ALCYU N/A
- IMNM 2006
- Country
- ALCYU
- IMNM United States
- Employees
- ALCYU 3
- IMNM N/A
- Industry
- ALCYU
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- ALCYU
- IMNM Health Care
- Exchange
- ALCYU NYSE
- IMNM Nasdaq
- Market Cap
- ALCYU N/A
- IMNM 747.7M
- IPO Year
- ALCYU N/A
- IMNM 2020
- Fundamental
- Price
- ALCYU $10.98
- IMNM $10.97
- Analyst Decision
- ALCYU
- IMNM Strong Buy
- Analyst Count
- ALCYU 0
- IMNM 5
- Target Price
- ALCYU N/A
- IMNM $28.60
- AVG Volume (30 Days)
- ALCYU N/A
- IMNM 911.8K
- Earning Date
- ALCYU N/A
- IMNM 11-13-2024
- Dividend Yield
- ALCYU N/A
- IMNM N/A
- EPS Growth
- ALCYU N/A
- IMNM N/A
- EPS
- ALCYU N/A
- IMNM N/A
- Revenue
- ALCYU N/A
- IMNM $10,129,000.00
- Revenue This Year
- ALCYU N/A
- IMNM N/A
- Revenue Next Year
- ALCYU N/A
- IMNM N/A
- P/E Ratio
- ALCYU N/A
- IMNM N/A
- Revenue Growth
- ALCYU N/A
- IMNM N/A
- 52 Week Low
- ALCYU N/A
- IMNM $8.33
- 52 Week High
- ALCYU N/A
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- ALCYU 46.01
- IMNM 39.61
- Support Level
- ALCYU $11.07
- IMNM $10.76
- Resistance Level
- ALCYU $11.10
- IMNM $15.13
- Average True Range (ATR)
- ALCYU 0.00
- IMNM 0.98
- MACD
- ALCYU -0.00
- IMNM -0.29
- Stochastic Oscillator
- ALCYU 0.00
- IMNM 4.81
About ALCYU ALCHEMY INVTS ACQUISITION CORP 1 UNIT 1 CL A COM & 1/2 WT
Alchemy Investments Acquisition Corp 1 is a blank check company.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.